Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Pilot Study of Losmapimod in FSHD1 with Extension
2024-512736-29-00Phase 2Completed
- Sponsor
- Fulcrum Therapeutics
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of losmapimod in facioscapulohumeral muscular dystrophy type 1 (FSHD1), sponsored by Fulcrum Therapeutics. Primary endpoint: Safety and tolerability based on AEs, clinical laboratory test results, ECGs, and vital signs. Started Jun 2024; status: completed.
02
Drugs
losmapimod
03
Conditions
facioscapulohumeral muscular dystrophy type 1 (FSHD1)
Beyond the preview
Go deeper on 2024-512736-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512736-29-00.